Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults
Clinical trial NCT00921947 · COMPLETED
Trial details
- NCT number
- NCT00921947
- Sponsor
- VaxInnate Corporation
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-06-01
- Primary completion
- 2009-07-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.